dermatology
Autoimmune diseases

Psoriatic arthritis: what Cochrane tells us about MTX vs bDMARDs


While the use of methotrexate in RA is well supported by evidence, the same cannot be said for its use in psoriatic arthritis (PsA), an Australian led Cochrane Review has shown. The first systematic review of the evidence for the conventional synthetic DMARD (csDMARD) in PsA has found only low-quality evidence from one trial showing ...

Already a member?

Enter your email to keep reading.


OR